Featured Insights

Journal

KnolSights Journal | Ulcerative Colitis

September 1, 2025

Ulcerative colitis is a chronic inflammatory disease of the colon, affecting approximately 1% of the US population-about 1.9 million people-and with a prevalence ranging from 156 to 291 cases per 100,000 globally. While mortality rates are generally low, the condition often leads to substantial morbidity and long-term health challenges. Explore the latest findings and therapeutic breakthroughs in our ulcerative colitis journal.

Journal

KnolSights Journal | Diabetes Type-1

September 1, 2025

Type 1 diabetes is an autoimmune condition in which the body’s immune system destroys insulin-producing cells in the pancreas, requiring lifelong insulin therapy. With the global number of cases projected to rise to as many as 17.4 million by 2040, our journals provide essential updates on breakthroughs in treatment and management for those living with type 1 diabetes.

Select your product of interest

Thank you! Your request has been received.

Featured Insights

KnolSights Journal | Ulcerative Colitis

KnolSights Journal | Diabetes Type-1

Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025

Amgen announced that new data from its cardiovascular portfolio, including results from the Phase 3 VESALIUS-CV clinical trial of Repatha (evolocumab)...

Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

Genentech announced positive results from the Phase III ALLEGORY study of Gazyva in adults with systemic lupus erythematosus (SLE) on standard therapy...

GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc Analysis

Myriad Genetics announced a post-hoc analysis of the PRIME study, revealing that patients with Major Depressive Disorder (MDD) treated based on GeneSi...

Foghorn Therapeutics Announces Updates for Selective ARID1B, CBP, and EP300 Degrader Programs

Foghorn Therapeutics announced updates on its Selective ARID1B, CBP, and EP300 degrader programs. The Selective ARID1B degrader selectively binds and ...

Wave Life Sciences Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity

Wave Life Sciences announced positive Activin E target engagement data from the INLIGHT clinical trial of WVE-007, a GalNAc-siRNA, for obesity. The tr...

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

AnaptysBio announced positive late-breaking data from its Phase 2b trial of rosnilimab in rheumatoid arthritis (RA). The study demonstrated deepening ...

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

AbbVie announced positive topline results from two replicate Phase 3 studies evaluating upadacitinib (RINVOQ®) in adult and adolescent patients with n...

TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial of Simplified Dosing for BRIUMVI in Multiple Sclerosis

TG Therapeutics announced the completion of enrollment in the Phase 3 ENHANCE trial, which is evaluating a simplified dosing schedule for BRIUMVI (ubl...

Kyverna Therapeutics Announces Positive Phase 2 Interim Data for KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics announced positive interim Phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis (gMG). The data showed ...

Sionna Therapeutics Announces Phase 1 Data for SION-719 and SION-451 and Preclinical Data on NBD1 Stabilizers in Cystic Fibrosis

Sionna Therapeutics announced the presentation of Phase 1 clinical trial data for SION-719 and SION-451, first-in-class NBD1 stabilizers, at the 2025 ...

Daewoong Pharmaceutical's Bersiporocin Receives Positive IDMC Safety Review in Phase 2 IPF Trial

Daewoong Pharmaceutical announced that Bersiporocin (DWN12088), its first-in-class drug candidate for idiopathic pulmonary fibrosis (IPF), received a ...

Innovent's Mazdutide Demonstrates Superior Glycemic Control and Weight Loss Compared to Semaglutide in Phase 3 DREAMS-3 Trial

Innovent Biologics announces positive results from its Phase 3 DREAMS-3 clinical trial of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (G...

Akeso's Ivonescimab Receives Breakthrough Therapy Designation in China for Triple-Negative Breast Cancer

Akeso's ivonescimab, a PD-1/VEGF bispecific antibody, has been granted Breakthrough Therapy Designation (BTD) by China's National Medical Products Adm...

Vizient Applauds FDA Actions to Accelerate Biosimilar Development and Lower Costs

Vizient commends the FDA for announcing actions to accelerate biosimilar development, including releasing new draft guidance that provides greater cla...

FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) for Pulmonary Arterial Hypertension Based on Phase 3 ZENITH Study

Merck announced that the FDA has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) based on the Phase 3 ZENITH trial. The...

FDA Approves Genentech's Gazyva for Lupus Nephritis Treatment

The FDA has approved Genentech's Gazyva (obinutuzumab) for treating adult patients with active lupus nephritis (LN) receiving standard therapy. The ap...

OS Therapies Receives FDA and MHRA Feedback on OST-HER2 for Metastatic Osteosarcoma

OS Therapies Inc. announced that the FDA granted a Type C meeting to discuss clinical efficacy data endpoints for a BLA under the Accelerated Approval...

Civica to Launch Affordable Long-Acting Insulin Glargine in the US

Non-profit pharmaceutical company Civica is set to launch a long-acting insulin, insulin glargine-yfgn, in pre-filled pens at the lowest list price in...

Novartis to Acquire Avidity Biosciences for $12 Billion

Novartis AG will acquire Avidity Biosciences for USD 72.00 per share in cash, valuing the company at approximately USD 12.0 billion. Avidity will sepa...

Innovent and Takeda Partner to Develop Next-Gen IO and ADC Therapies

Innovent Biologics and Takeda have entered into a global strategic partnership to co-develop and commercialize Innovent's next-generation immuno-oncol...

Boehringer Ingelheim and AimedBio Collaborate to Advance Novel ADC Therapy for Broad Range of Cancers

Boehringer Ingelheim and AimedBio have entered into a global collaboration and licensing agreement to develop a novel antibody-drug conjugate (ADC) th...

Biocon Biologics and Civica Expand Partnership to Launch Insulin Glargine for U.S. Diabetes Patients

Biocon Biologics and Civica expand their partnership to include Insulin Glargine, aiming to increase the availability of affordable insulin for the 38...

Novo Nordisk to Acquire Akero Therapeutics for up to $5.2 Billion

Akero Therapeutics, a clinical-stage company focused on metabolic diseases, has entered into a definitive agreement to be acquired by Novo Nordisk for...

MaxCyte and Moonlight Bio Partner to Advance T Cell Therapies for Solid Tumors

MaxCyte and Moonlight Bio have entered into a Strategic Platform License agreement. Moonlight Bio will utilize MaxCyte’s Flow Electroporation® technol...

Elutia Closes BioEnvelope Business Sale to Boston Scientific for $88 Million, Focuses on NXT-41x for Breast Reconstruction Infections

Elutia Inc. has finalized the sale of its BioEnvelope business, including EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation for $88...

Roche to Acquire 89bio for MASH Therapy Development

Roche has entered into a definitive merger agreement to acquire 89bio, Inc., a clinical-stage biopharmaceutical company, for up to $3.5 billion. The a...

Novartis Acquires Tourmaline Bio for $1.4 Billion, Expanding Cardiovascular Pipeline with Pacibekitug

Novartis announced its acquisition of Tourmaline Bio, a clinical-stage biopharmaceutical company, for approximately $1.4 billion. The acquisition cen...

Zydus and Synthon Partner for Ozanimod Capsules in the US Market

Zydus Lifesciences and Synthon BV have entered into an exclusive licensing and supply agreement for Ozanimod Capsules, a generic version of ZEPOSIA®, ...

Journals

KnolSights Journal | Ulcerative Colitis

KnolSights Journal | Obesity

KnolSights Journal | Diabetes Type-1

KnolSights Journal | Major Depressive Disorder